Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin clearance goals among patients with eczema. | Lynk Pharmaceuticals has reported ...

Among patients with moderate to severe atopic dermatitis, APG777 produced significant reductions in disease severity at 16 weeks.

Organon reports Phase 3 data showing VTAMA improved sleep in children as young as two with atopic dermatitis, reinforcing its dermatology push.

Daily application of roflumilast cream for 52 weeks improves the signs and symptoms of AD in patients with various comorbid atopic conditions.

Lebrikizumab is an interleukin-13 antagonist approved as Ebglyss for the treatment of adults and pediatric patients with moderate to severe atopic dermatitis.

Eczema and dermatitis are two terms that often confuse, as they are frequently used interchangeably to describe skin inflammation. However, while the two are closely related, they are not entirely the ...

Recently published Atopic Dermatitis Market Insights report includes a comprehensive understanding of current treatment ...

Adults with atopic dermatitis and chronic hand eczema saw early and sustained improvements in skin and quality of life measures with tralokinumab compared with placebo, according to a poster presented ...

The data suggest significant challenges in maintaining long-term disease control with advanced systemic therapies for atopic dermatitis.

Experts break down the most important facts about atopic dermatitis on the hands, including risk factors, treatments, and tips for soothing relief. Atopic dermatitis (AD), the most common form of ...

Among patients aged 2 to 17 years with moderate to severe atopic dermatitis, tapinarof cream 1% significantly improved sleep, ...

If your current atopic dermatitis treatment isn’t working, it’s time for a change. Learn how the latest oral therapies can help you thrive.